Background Metastatic colorectal cancer, mCRC, is a group of distinct diseases, with clinical and molecular differences between right-sided and left-sided tumors driving varying prognosis. Patients with KRAS/RAS-wild type (wt) mCRC…
When was it reported? The outcome of the phase II, multicenter, open-label, single-arm DESTINY-Breast trial was reported at the 2019 San Antonio Breast Cancer Symposium, SABCS, from December 10 –…
In short The results of a phase II trial in patients with BRAF V600E mutations in high- and low-grade glioma, were reported at the 24th meeting of the Society for…
Interim results The virus has been designated a breakthrough therapy in Japan. An interim analysis of a trial of the oncolytic herpes virus G47∆ has shown a 1-year survival rate…
Background According to interim findings of a phase II trial, the combination of INO-5401, a T-cell–activating immunotherapy and INO-9012, an immune activator of a different kind with Libtayo (Cemiplimab, a…
Background There is significant unmet medical need following treatment with Herceptin, Perjeta and Kadcyla in patients with metastatic HER2-positive breast cancer. In the HER2CLIMB trial, the addition of tucatinib to…
This time, we'll start from the end... Results of the study First of all, it is important to note that the research goals were not achieved in the entire study…
Many small cell lung cancer patients rapidly relapse due to the aggressive nature of the disease. While the current standard of care in the second-line setting can extend survival, treatment…
The Food and Drug Administration, the FDA, has granted capmatinib a “breakthrough therapy” designation as a first-line treatment for Non-Small Cell Lung Cancer (NSCLC) patients with MET mutation, EGFR Wild-type…
The main therapeutic objectives in treating metastatic disease are prolonging life (also called “Survival”) and Quality of Life (QoL), knowing the disease will stay in the body for life. ***…